CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Sign Up to like & getrecommendations! Published in 2019 at "Nature Communications"
DOI: 10.1038/s41467-018-08123-8
Abstract: Agonist antibodies (Ab) directed against costimulatory molecules on the surface of antigen-primed T cells are in various stages of pre-clinical and clinical trials, albeit with limited therapeutic benefit as single agents. The underlying mechanisms of… read more here.
Keywords: anti 1bb; therapy; resistance anti; cd73 expression ... See more keywords
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0647
Abstract: Purpose: VEGF-targeted therapies have modest efficacy in cancer patients, but acquired resistance is common. The mechanisms underlying such resistance are poorly understood. Experimental Design: To evaluate the potential role of immune cells in the development… read more here.
Keywords: anti vegf; vegf; resistance anti; resistance ... See more keywords
Abstract PD4-08: A microenvironment secretome screen reveals FGF2 as a mediator of resistance to anti-estrogens and PI3K/mTOR pathway inhibitors in ER+ breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-pd4-08
Abstract: Despite the clinical success of anti-estrogen therapies, phosphatidylinositol 3-kinase inhibitors (PI3Ki), and mechanistic target of rapamycin complex I inhibitors (mTORC1i) for the treatment of patients with ER+ breast cancer, disease recurrence and progression are common.… read more here.
Keywords: cancer; fgf2; resistance anti; breast cancer ... See more keywords
Qa-1b Modulates Resistance to Anti–PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-20-0652
Abstract: Immune checkpoint blockade (ICB) has improved cancer care, but ICB is only effective in some patients. The molecular mechanisms that influence ICB therapy response are not completely understood. The non-classical MHC class I molecule HLA-E… read more here.
Keywords: immune checkpoint; resistance anti; antigen processing; anti pd1 ... See more keywords
IN VIVO SYNGENEIC TUMOR MODELS WITH ACQUIRED RESISTANCE TO ANTI-PD-1/PD-L1 THERAPIES.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0802
Abstract: Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of cancer patients. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this… read more here.
Keywords: acquired resistance; resistant models; resistance anti; resistance ... See more keywords
IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.6053
Abstract: 6053Background: Patients with recurrent/metastatic human papillomavirus-associated head and neck squamous cell carcinoma (HPV-HNSCC) demonstrate improved response rates to anti-PD-1 blockade, which... read more here.
Keywords: adaptive immune; immune resistance; ido1 mechanism; resistance anti ... See more keywords
Regulating Resistance: From Anti to Counter-Revolutionary Practice - and Back Again - in Bahrain
Sign Up to like & getrecommendations! Published in 2021 at "Partecipazione e Conflitto"
DOI: 10.1285/i20356609v14i2p743
Abstract: On 14 February 2011 Bahrainis took to the streets demanding political reform as part of a broader wave of protests that swept across the Arab world. In the months that followed, the ruling Al-Khalifa family… read more here.
Keywords: counter revolutionary; counter; regulating resistance; resistance anti ... See more keywords
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.876048
Abstract: Immunotherapy treatments, particularly immune checkpoint blockade, can result in benefits in clinical settings. But many pre-clinical and clinical studies have shown that resistance to anti-PD1 therapy frequently occurs, leading to tumor recurrence and treatment failure,… read more here.
Keywords: resistance anti; anti pd1; pd1 therapy; pd1 ... See more keywords